Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis

Subacute sclerosing panencephalitis (SSPE) is a late-onset, intractable, and fatal viral disease caused by persistent infection of the central nervous system by a mutant strain of the measles virus. Ribavirin intracerebroventricular therapy has already been administered to several SSPE patients in J...

Full description

Bibliographic Details
Main Authors: Koichi Hashimoto, Mitsuaki Hosoya
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/26/2/427
id doaj-2b391b682225469eb726145002b9bbad
record_format Article
spelling doaj-2b391b682225469eb726145002b9bbad2021-01-16T00:01:28ZengMDPI AGMolecules1420-30492021-01-012642742710.3390/molecules26020427Advances in Antiviral Therapy for Subacute Sclerosing PanencephalitisKoichi Hashimoto0Mitsuaki Hosoya1Department of Pediatrics, School of Medicine, Fukushima Medical University, Fukushima 9601295, JapanDepartment of Pediatrics, School of Medicine, Fukushima Medical University, Fukushima 9601295, JapanSubacute sclerosing panencephalitis (SSPE) is a late-onset, intractable, and fatal viral disease caused by persistent infection of the central nervous system by a mutant strain of the measles virus. Ribavirin intracerebroventricular therapy has already been administered to several SSPE patients in Japan based on fundamental and clinical research findings from our group, with positive therapeutic effects reported in some patients. However, the efficacy of this treatment approach has not been unequivocally established. Hence, development of more effective therapeutic methods using new antiviral agents is urgently needed. This review describes the current status of SSPE treatment and research, highlighting promising approaches to the development of more effective therapeutic methods.https://www.mdpi.com/1420-3049/26/2/427SSPEribavirintherapyantiviral agent
collection DOAJ
language English
format Article
sources DOAJ
author Koichi Hashimoto
Mitsuaki Hosoya
spellingShingle Koichi Hashimoto
Mitsuaki Hosoya
Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis
Molecules
SSPE
ribavirin
therapy
antiviral agent
author_facet Koichi Hashimoto
Mitsuaki Hosoya
author_sort Koichi Hashimoto
title Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis
title_short Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis
title_full Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis
title_fullStr Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis
title_full_unstemmed Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis
title_sort advances in antiviral therapy for subacute sclerosing panencephalitis
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2021-01-01
description Subacute sclerosing panencephalitis (SSPE) is a late-onset, intractable, and fatal viral disease caused by persistent infection of the central nervous system by a mutant strain of the measles virus. Ribavirin intracerebroventricular therapy has already been administered to several SSPE patients in Japan based on fundamental and clinical research findings from our group, with positive therapeutic effects reported in some patients. However, the efficacy of this treatment approach has not been unequivocally established. Hence, development of more effective therapeutic methods using new antiviral agents is urgently needed. This review describes the current status of SSPE treatment and research, highlighting promising approaches to the development of more effective therapeutic methods.
topic SSPE
ribavirin
therapy
antiviral agent
url https://www.mdpi.com/1420-3049/26/2/427
work_keys_str_mv AT koichihashimoto advancesinantiviraltherapyforsubacutesclerosingpanencephalitis
AT mitsuakihosoya advancesinantiviraltherapyforsubacutesclerosingpanencephalitis
_version_ 1724336219240792064